A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT07619131
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT07619131 -
2026-525642-30-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Bulgaria, Canada, Denmark, Germany, Hungary, Israel, Poland, Spain, Ukraine, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07619131. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-12 (actual); primary completion 2027-07-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
- Condition
- Hypercholesterolaemia
- Intervention (Drug)
- Laroprovstat
- Intervention (Drug)
- Rosuvastatin 1
- Intervention (Drug)
- Rosuvastatin 2
- Intervention (Drug)
- Laroprovstat/Rosuvastatin 1
- Intervention (Drug)
- Placebo to match rosuvastatin
- Intervention (Drug)
- Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1
- Intervention (Drug)
- Laroprovstat/Rosuvastatin 2
- Intervention (Drug)
- Placebo to match Laroprovstat/Rosuvastatin 2
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07619131- Content hash
c7209b1953001a83af674eddae66568d341b18e6f7f1e579028b0e39b523f84f